Port Site Excision During Completion Extended Cholecystectomy for Incidental Gallbladder Cancer - A Scoping Review.
리뷰
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
170 patients who received PSE, 14 (8.
I · Intervention 중재 / 시술
PSE and those who did not
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
30-45 months), this difference was not statistically significant. [CONCLUSION] Routine PSE during CEC for iGBC may not be necessary, as it does not significantly reduce distant recurrence or improve overall survival.
[BACKGROUND] Completion extended cholecystectomy (CEC) is the standard treatment for incidental gallbladder cancer (iGBC) to reduce early recurrence and improve survival.
APA
Varshney VK, Singh S, et al. (2026). Port Site Excision During Completion Extended Cholecystectomy for Incidental Gallbladder Cancer - A Scoping Review.. Journal of gastrointestinal cancer, 57(1). https://doi.org/10.1007/s12029-026-01416-y
MLA
Varshney VK, et al.. "Port Site Excision During Completion Extended Cholecystectomy for Incidental Gallbladder Cancer - A Scoping Review.." Journal of gastrointestinal cancer, vol. 57, no. 1, 2026.
PMID
41779281 ↗
Abstract 한글 요약
[BACKGROUND] Completion extended cholecystectomy (CEC) is the standard treatment for incidental gallbladder cancer (iGBC) to reduce early recurrence and improve survival. However, the necessity of laparoscopic port site excision (PSE) during CEC remains controversial. This scoping review evaluates whether routine PSE is warranted in the management of iGBC.
[METHODS] A systematic search was conducted across PubMed, Google Scholar, Scopus, and the Cochrane Library using keywords such as "incidental gallbladder carcinoma," "radical cholecystectomy," "extended cholecystectomy," "port site excision," "port site recurrence," and "port site metastasis."
[RESULTS] Three original studies involving 503 iGBC patients were analyzed, comparing outcomes between those who underwent PSE and those who did not. Of the 170 patients who received PSE, 14 (8.2%) had malignant port site involvement. Recurrence rates were comparable between the PSE and non-PSE groups (36% vs. 40%). Although the median overall survival was numerically higher in the PSE group (36-89 months vs. 30-45 months), this difference was not statistically significant.
[CONCLUSION] Routine PSE during CEC for iGBC may not be necessary, as it does not significantly reduce distant recurrence or improve overall survival.
[METHODS] A systematic search was conducted across PubMed, Google Scholar, Scopus, and the Cochrane Library using keywords such as "incidental gallbladder carcinoma," "radical cholecystectomy," "extended cholecystectomy," "port site excision," "port site recurrence," and "port site metastasis."
[RESULTS] Three original studies involving 503 iGBC patients were analyzed, comparing outcomes between those who underwent PSE and those who did not. Of the 170 patients who received PSE, 14 (8.2%) had malignant port site involvement. Recurrence rates were comparable between the PSE and non-PSE groups (36% vs. 40%). Although the median overall survival was numerically higher in the PSE group (36-89 months vs. 30-45 months), this difference was not statistically significant.
[CONCLUSION] Routine PSE during CEC for iGBC may not be necessary, as it does not significantly reduce distant recurrence or improve overall survival.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.